The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette–GuerinFootnote

Peer review under responsibility of Arab Association of Urology.

References

• W.OosterlinckB.LobelG.JakseP.-U.MalmstromM.StockleC.SternbergGuidelines on Bladder Cancer2003European Association of UrologyArnhem
   Google Scholar
• M.C.HallS.S.ChangG.DalbagniJ.D.SeigneE.C.SkinnerThe Bladder Cancer Clinical Guideline Update Panel. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis)J Urol2007178200723142330 Update
   Google Scholar
• L.CormioI.TolveP.AnneseA.SaracinoR.ZampareseF.Sanguedolceet alAltered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancerAnticancer Res29200942014204
   Web of Science ®Google Scholar
• L.NakopoulouC.VourlakouA.ZervasA.TzonouH.GakiopoulouM.A.DimopoulosThe prevalence of bcl-2, 53, and Ki-67 immunoreactivity in transitional cell bladder carcinoma and their clinicopathologic correlatesHum Pathol291998146154
   PubMed Web of Science ®Google Scholar
• Z.PopovA.HoznekM.ColombelS.Bastuji-GarinM.A.Lefrere-BeldaJ.Bellotet alThe prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladderCancer80199714721481
   PubMed Web of Science ®Google Scholar
• H.OvesenT.HornK.StevenLong-term efficacy of intravesical Bacillus Calmette–Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulationJ Urol157199716551659
   Web of Science ®Google Scholar
• T.LebretV.BecetteM.BarbagelattaJ.M.HerveF.GaudezP.Barreet alCorrelation between p53 over expression and response to Bacillus Calmette–Guerin therapy in a high risk select population of patients with T1G3 bladder cancerJ Urol1591998788791
   PubMed Web of Science ®Google Scholar
• A.R.ZlottaJ.C.NoelI.FaytA.DrowartJ.P.Van VoorenK.Huygenet alCorrelation and prognostic significance of p53, 21WAF1/CIP1and Ki-67 expressions in patients with non muscle invasive bladder tumors treated with Bacillus Calmette-Guerin intravesical therapyJ Urol1611999792798
   PubMed Web of Science ®Google Scholar
• F.PagesT.A.FlamA.VieillefondX.AbeilleV.Lazaret alP53 status does not predict initial clinical response to Bacillus Calmette–Guerin intravesical therapy in T1 bladder tumorsJ Urol159199810791084
   PubMed Web of Science ®Google Scholar
• A.YangR.SchweitzerD.SunM.KaghadN.WalkerR.T.Bronsonet alP63 is essential for regenerative proliferation in limb, craniofacial, and epithelial developmentNature3981999714718
   PubMed Web of Science ®Google Scholar
• M.J.UristC.J.Di ComoM.L.LuE.CharytonowiczD.VerbelC.P.Crumet alLoss of p63 expression is associated with tumor progression in bladder cancerAm J Pathol161200211991206
   PubMed Web of Science ®Google Scholar
• B.J.ParkS.J.LeeJ.I.KimS.J.LeeC.H.LeeS.G.Changet alFrequent alteration of p63 expression in human primary bladder carcinomasCancer Res60200033703374
   PubMed Web of Science ®Google Scholar
• F.KogaS.KawakamiJ.KumagaiT.TakizawaN.AndoG.Araiet alImpaired DeltaNp63 expression associates with reduced beta-catenin. An aggressive phenotype of urothelial neoplasmsBr J Cancer882003740747
   PubMed Web of Science ®Google Scholar
• H.MatsubaraY.YamadaK.NaruseK.NakamuraS.AokiT.Takiet alPotential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma comparative study of immunohistochemistry and fluorescent in situ hybridizationOncol Rep1920085763
   PubMed Web of Science ®Google Scholar
• K.NaruseY.YamadaK.NakamuraS.AokiT.TakiK.Zennamiet alPotential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladderOncology Rep23201015771583
   PubMed Web of Science ®Google Scholar
• H.OlssonI.M.FyhrP.HultmanS.JahnsonHER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladderScand J Urol Nephrol462012102107
   PubMed Web of Science ®Google Scholar
• S.SimonettiR.RussoG.CianciaV.AltieriG.De RosaL.InsabatoRole of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17Int J Surg Pathol172009198205
   PubMed Web of Science ®Google Scholar
• L.SkagiasE.PolitiA.KaramerisD.SambaziotisA.ArchondakisO.Vasouet alPrognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years’ researchJ BUON142009457462
   PubMed Web of Science ®Google Scholar
• J.N.EbleG.SauterJ.I.EpsteinI.A.SesterhennPathology and Genetics of Tumours of the Urinary System and Male Genital Organs2004IARCLyon
   Google Scholar
• L.H.SobinM.K.GospodarowiczC.WittekindTNM Classification of Malignant Tumours7th ed.2009WileyWeinheim
   Google Scholar
• H.W.HerrV.P.LaudoneR.A.BadalamentH.F.OettgenC.S.PramodB.D.Freedmanet alBacillus Calmette–Guerin therapy alters the progression of non muscle invasive bladder cancerJ Clin Oncol6198814501455
   PubMed Web of Science ®Google Scholar
• F.SaintBelda M.Le FrereR.QuintelaA.HoznekJ.J.PatardJ.Bellotet alRetreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette–Guérin (BCG)Eur Urol452004475482
   PubMed Web of Science ®Google Scholar
• L.LacombeG.DalbagniZ.F.ZhangC.Cordon-CardoW.R.FairH.W.Heret alOverexpression of p53 protein in a high-risk population of patients with non muscle invasive bladder cancer before and after Bacillus Calmette–Guerin therapy: correlation to clinical outcomeJ Clin Oncol14199626462652
   PubMed Web of Science ®Google Scholar
• M.NishizakiT.FujiwaraT.TanidaA.HizutaH.NishimoriT.Tokinoet alRecombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanisms for bystander effectClin Cancer Res5199910151023
   PubMed Web of Science ®Google Scholar
• C.PfisterJ.M.FlamanF.DunetP.GriseT.FrebourgP53 mutations in bladder tumors inactivate the transactivation of the P21 and BAX genes, and have a predictive value for the clinical outcome after Bacillus Calmette–GuerinJ Urol16219996973
   PubMed Web of Science ®Google Scholar
• K.IckM.SchultzP.StoutK.FanSignificance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after Bacillus Calmette–Guerin treatmentUrology491997541547
   PubMed Web of Science ®Google Scholar
• C.J.Di ComoM.J.UristI.BabayanM.DrobnjakC.V.HedvatJ.Teruya-Feldsteinet alP63 expression profiles in human normal and tumor tissuesClin Cancer Res82002494501
   PubMed Web of Science ®Google Scholar
• A.YangM.KaghadY.WangE.GillettM.D.FlemingV.Dötschet alP63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activitiesMol Cell21998305316
   PubMed Web of Science ®Google Scholar
• B.E.MorganR.SalupM.B.MorganDifferential C-erbB-2 and VEGF expression following BCG immunotherapy in non muscle invasive papillary transitional cell carcinoma of the bladderUrol Oncol720026772
   Google Scholar
• A.AlexaiF.BadercaiD.ZahoiR.LighezaniD.IzvernariuiM.RaicaiClinical significance of Her2/neu overexpression in urothelial carcinomasRomanian J Morph Embryol512010277282
   Web of Science ®Google Scholar
• S.CharfiaA.KhabirH.MnifaS.EllouzeaM.MhiribT.SellamiaImmunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expressionJ Microsc Ultrastruct120131721
   Google Scholar